Objective: The aim of our study was to evaluate the efficacy of 89 Sr combined with Technetium [99Tc] Methylenediphosphonate Injection(99Tc-MDP) in the treatment of cancer pain in the advanced breast cancers with bone...Objective: The aim of our study was to evaluate the efficacy of 89 Sr combined with Technetium [99Tc] Methylenediphosphonate Injection(99Tc-MDP) in the treatment of cancer pain in the advanced breast cancers with bone metastases. Methods: A total of 80 patients with various degrees of bone pain due to multiple metastases of breast cancer were treated with 89 Sr combined with 99Tc-MDP. 89 Sr was given intravenously at 4m Ci on day 1 during the 3-month schedule. After 7 days, 99Tc-MDP was given at 22 mg/day on days 1–10 during the 1-month schedule, for 3 to 6 months. Results: The effective rate of relieving pain was 83.75%. The effective rate of curing bone metastases was 81.25%. So there was a significant improvement in the quality of life of the patients. Conclusion: 89 Sr combined with 99Tc-MDP are effective in the treatment of cancer pain in the breast cancers with bone metastasis, and can obviously repair the bone destruction caused by metastases, thereby improving the quality of life in advanced breast cancer patients with bone metastases.展开更多
Objective:The aim of this study was to evaluate the efficacy and safety profile of DeFazio(S-1)combined with oxaliplatin against unresectable advanced or metastatic gastric cancer.Methods:Oxaliplatin was given intrave...Objective:The aim of this study was to evaluate the efficacy and safety profile of DeFazio(S-1)combined with oxaliplatin against unresectable advanced or metastatic gastric cancer.Methods:Oxaliplatin was given intravenously at 130mg/m2for 2 h on d1 and S-1 was administered bid.at 80 mg/m2/day on d1–14 followed by a 7-day rest during the 3-week schedule.Results:All 62 patients were assessed for efficacy and adverse events.The response and disease control rates were 47.3%and 80.8%,respectively.The median time to progression was 7.8 months,and the median overall survival was11.6 months.The grade 3/4 adverse events were hematological toxicities,including neutropenia(11.3%),thrombocytopenia(9.7%)and gastrointestinal reactions(6.5%).Conclusion:The SOX regimen(oxaliplatin,130 mg/m2d1;S-1,80 mg/m2/day,bid.d1-14,q3w)provide a favorable efficacy and safety profile in patients with advanced gastric cancer.展开更多
文摘Objective: The aim of our study was to evaluate the efficacy of 89 Sr combined with Technetium [99Tc] Methylenediphosphonate Injection(99Tc-MDP) in the treatment of cancer pain in the advanced breast cancers with bone metastases. Methods: A total of 80 patients with various degrees of bone pain due to multiple metastases of breast cancer were treated with 89 Sr combined with 99Tc-MDP. 89 Sr was given intravenously at 4m Ci on day 1 during the 3-month schedule. After 7 days, 99Tc-MDP was given at 22 mg/day on days 1–10 during the 1-month schedule, for 3 to 6 months. Results: The effective rate of relieving pain was 83.75%. The effective rate of curing bone metastases was 81.25%. So there was a significant improvement in the quality of life of the patients. Conclusion: 89 Sr combined with 99Tc-MDP are effective in the treatment of cancer pain in the breast cancers with bone metastasis, and can obviously repair the bone destruction caused by metastases, thereby improving the quality of life in advanced breast cancer patients with bone metastases.
文摘Objective:The aim of this study was to evaluate the efficacy and safety profile of DeFazio(S-1)combined with oxaliplatin against unresectable advanced or metastatic gastric cancer.Methods:Oxaliplatin was given intravenously at 130mg/m2for 2 h on d1 and S-1 was administered bid.at 80 mg/m2/day on d1–14 followed by a 7-day rest during the 3-week schedule.Results:All 62 patients were assessed for efficacy and adverse events.The response and disease control rates were 47.3%and 80.8%,respectively.The median time to progression was 7.8 months,and the median overall survival was11.6 months.The grade 3/4 adverse events were hematological toxicities,including neutropenia(11.3%),thrombocytopenia(9.7%)and gastrointestinal reactions(6.5%).Conclusion:The SOX regimen(oxaliplatin,130 mg/m2d1;S-1,80 mg/m2/day,bid.d1-14,q3w)provide a favorable efficacy and safety profile in patients with advanced gastric cancer.
